Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...
Clearside eye disease candidate aces exam in pursuit of Roche's Vabysmo and Regeneron, Bayer's Eylea
A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...
Istaroxime is a novel first-in-class investigational therapy that is intended to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining ...
The annual meeting of the American Society for Radiation Oncology was held from Sept. 29 to Oct. 2 in Washington, D.C., ...
A new tool detects the evolutionary advantages of multiple myeloma cells over the different treatments available. The information it provides can help prevent the tumor from becoming resistant to ...
A new study highlights that disparities in extended treatments, economic burdens, and healthcare access are behind the rising breast cancer death rates among Black women.
The investigational IL-17A inhibitor izokibep was found to induce clear clinical responses in people with moderate to severe ...
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...
Topical delgocitinib appears more effective than oral alitretinoin and is comparable to dupilumab for treating types of hand eczema, according to two separate studies.
An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback